CSL – Citi rates the stock as Buy

By Broker News | More Articles by Broker News

CSL had earlier flagged that transitioning to its own distribution channel in China would have a one-off impact on FY20 financials. On Friday the company quantified this impact in the form of a decline in albumin sales by -US$340-US$370m.

Citi analysts estimate the impact on net profits will be around -6% with the impact on cash flows to be much lower, also because CSL will continue to collect outstanding receivables from existing distributors despite the accountancy change/delay. Buy. Target unchanged at $236.60.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $236.60.Current Price is $212.12. Difference: $24.48 – (brackets indicate current price is over target). If CSL meets the Citi target it will return approximately 10% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →